UCB Pharma GmbH successfully dodged a bid to kill its patent on an ingredient in a drug to treat urinary incontinence.
The U.S. Court of Appeals for the Federal Circuit Jan. 11 rejected arguments by Amerigen Pharmaceuticals that UCB’s U.S. patent 6,858,650 was obvious in light of prior research and therefore invalid. The ruling affirmed a decision by the Patent Trial and Appeal Board.
The patent relates to chemical derivatives including the compound fesoterodine, the active ingredient in Toviaz, which is licensed to Pfizer Inc. Amerigan challenged the patent’s validity as part of its effort to market a generic version...
For more stories, analysis and expertiseOR Request Trial
(Updated with additional reporting throughout)